TG Therapeutics, Inc.
4 clinical trials · 4 recruiting · INDUSTRY
Trials by TG Therapeutics, Inc.
RECRUITINGPhase 1NCT06680037
A Study to Assess the Safety and Clinical Activity of Azer-cel in Participants With B-cell Mediated Autoimmune Disorders
The main objective of the study is to determine the recommended phase 2 dose (RP2D) of Azercabtagene zapreleucel (azer-cel).
Sponsor: TG Therapeutics, Inc.Enrolling: 328 locations
B-cell Mediated Autoimmune Disorders
RECRUITINGPhase 3NCT05877963
Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
The primary purpose of this phase 3b study is to assess the efficacy of a modified regimen of ublituximab in participants with relapsing multiple sclerosis (RMS) as measured by T1...
Sponsor: TG Therapeutics, Inc.Enrolling: 80020 locations
Relapsing Multiple Sclerosis
RECRUITINGPhase 3NCT07211633
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Radiological and Clinical Effects of Subcutaneous...
The purpose of this study is to assess the pharmacokinetics of ublituximab when administered subcutaneously (SC) compared to intravenous (IV) administration in participants with...
Sponsor: TG Therapeutics, Inc.Enrolling: 36020 locations
Relapsing Multiple Sclerosis
RECRUITINGNCT06433752
A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing...
The purpose of this study is to evaluate safety, effiectiveness, and to gain insight into the treatment experience of participants prescribed BRIUMVI® (ublituximab-xiiy) in the...
Sponsor: TG Therapeutics, Inc.Enrolling: 50020 locations
Relapsing Multiple SclerosisMultiple Sclerosis